NCT04945330View on ClinicalTrials.gov

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

November 5, 2021

Primary Completion Date

June 30, 2029

Study Completion Date

December 31, 2029

Conditions
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
Interventions
DRUG

Larotrectinib (Vitrakvi, BAY2757556)

Follow clinical practice

Trial Locations (1)

Unknown

RECRUITING

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY